This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, M. Articles by Lawrence, T. S. Search for Related Content PubMed PubMed Citation Articles by Zhang, M. Articles by Lawrence, T. S.

Regional Delivery and Selective Expression of a High-Activity Yeast Cytosine Deaminase in an Intrahepatic Colon Cancer Model¹

Departments of Radiation Oncology [M. Z., S. L., M. K. N., A. R., T. S. L.] and Pharmacology [S. D., J. P., W. D. E.], University of Michigan Medical School, Ann Arbor, Michigan 48109

A major potential limitation to the success of enzyme prodrug gene therapy is the toxicity that could result from gene expression in normal tissues. In this study, we investigated the use of an enhanced human carcinoembryonic antigen (CEA) promoter for yeast cytosine deaminase (yCD), which converts 5-fluorocytosine to 5-fluorouracil, to increase targeting while maintaining activity both in cell culture and in nude rats bearing intrahepatic xenografts. We found that an enhanced CEA-yCD adenoviral vector can achieve significantly greater yCD expression in CEA-expressing colon carcinoma cell lines (LoVo, HT29, and CaCo2) compared with a nonspecific Rous sarcoma virus-yCD virus. In contrast, infection with CEA-yCD led to lower or equivalent yCD expression in normal hepatocytes or fibroblasts compared with that produced by the RSV-yCD. Adenovirus administered in the portal vein or the hepatic artery of nude rats bearing intrahepatic LoVo colon carcinomas could mediate ß-galactosidase expression equally in liver and tumors under the control of cytomegalovirus, a nonspecific promoter. However, infusion of CEA-yCD virus markedly increased yCD expression in tumors over normal liver (>4-fold) measured both by levels of mRNA and yCD activity. Moreover, the efficiency of 5-fluorocytosine conversion into 5-fluorouracil in tumors was significantly higher than that in normal liver (3-fold) in rats receiving portal venous viral infusion of CEA-yCD and subsequent 5FC treatment. Thus, an enhanced CEA promoter can preferentially stimulate yCD gene expression in CEA-expressing cells in vivo. Such tumor-specific expression should prove useful in colorectal cancer gene therapy to achieve selective prodrug conversion in tumors.

This article has been cited by other articles:

				K. Hiraoka, T. Kimura, C. R. Logg, C.-K. Tai, K. Haga, G. W. Lawson, and N. Kasahara Therapeutic Efficacy of Replication-Competent Retrovirus Vector-Mediated Suicide Gene Therapy in a Multifocal Colorectal Cancer Metastasis Model Cancer Res., June 1, 2007; 67(11): 5345 - 5353. [Abstract] [Full Text] [PDF]

				K. Hiraoka, T. Kimura, C. R. Logg, and N. Kasahara Tumor-Selective Gene Expression in a Hepatic Metastasis Model after Locoregional Delivery of a Replication-Competent Retrovirus Vector Clin. Cancer Res., December 1, 2006; 12(23): 7108 - 7116. [Abstract] [Full Text] [PDF]

				P. Flaherty, G. Giaever, J. Kumm, M. I. Jordan, and A. P. Arkin A latent variable model for chemogenomic profiling Bioinformatics, August 1, 2005; 21(15): 3286 - 3293. [Abstract] [Full Text] [PDF]